Prognostic scoring system for XXXX : the International @entity706 Study Group experience.

@entity1 @entity706 @entity5 @entity880 @entity1499 @entity2841
PURPOSE: To identify survival predictors and to design a prognostic score useful for distinguishing risk groups in immunocompetent @entity1 with @entity706 ( @entity706 ). @entity1 AND METHODS: The prognostic role of @entity1 -, lymphoma-, and treatment-related variables was analyzed in a multicenter series of 378 @entity706 @entity1 treated at 23 @entity5 centers from five different countries. RESULTS: Age more than 60 years, performance status (PS) more than 1, elevated @entity880 dehydrogenase (LDH) serum level, high @entity2841 protein concentration, and involvement of deep regions of the brain (periventricular regions, basal ganglia, brainstem, and/or cerebellum) were significantly and independently associated with a worse survival. These five variables were used to design a prognostic score. Each variable was assigned a value of either 0, if favorable, or 1, if unfavorable. The values were then added together to arrive at a final score, which was tested in 105 assessable @entity1 for which complete data of all five variables were available. The 2-year overall survival (OS) +/- SD was 80% +/- 8%, 48% +/- 7%, and 15% +/- 7% (P =.00001) for @entity1 with zero to one, two to three, and four to five unfavorable features, respectively. The prognostic role of this score was confirmed by limiting analysis to assessable @entity1 treated with high-dose @entity1499 -based chemotherapy (2-year OS +/- SD: 85% +/- 8%, 57% +/- 8%, and 24% +/- 11%; P =.0004). CONCLUSION: Age, PS, LDH serum level, @entity2841 protein concentration, and involvement of deep structures of the brain were independent predictors of survival. A prognostic score including these five parameters seems advisable in distinguishing different risk groups in @entity706 @entity1 . The proposed score and its relevance in therapeutic decision deserve to be validated in further studies.
